Vir Biotechnology to present expanded Phase 2 SOLSTICE data on elebsiran-tobevibart combo in hepatitis delta at

Vir Biotechnology will present expanded Phase 2 SOLSTICE data on its elebsiran with tobevibart combination therapy for chronic hepatitis delta at AASLD The Liver Meeting 2026 in Denver. The update through Week 96 will focus on efficacy, and a separate presentation will cover a translational sub-study on intrahepatic immune-cell changes.